Show simple item record

dc.contributor.authorArama, Victoria
dc.contributor.authorLeblebicioglu, Hakan
dc.contributor.authorSimon, Krzysztof
dc.contributor.authorZarski, Jean Pierre
dc.contributor.authorNiederau, Claus
dc.contributor.authorHabersetzer, Francois
dc.contributor.authorZeuzem, Stefan
dc.date.accessioned2020-06-21T13:58:20Z
dc.date.available2020-06-21T13:58:20Z
dc.date.issued2014
dc.identifier.issn1359-6535
dc.identifier.urihttps://doi.org/10.3851/IMP2719
dc.identifier.urihttps://hdl.handle.net/20.500.12712/15360
dc.descriptionLeblebicioglu, Hakan/0000-0002-6033-8543; Suceveanu, Andra Iulia/0000-0001-8669-4952; Plesniak, Robert/0000-0001-7041-6472; SIEKLUCKI, JERZY/0000-0002-8463-1672; Simon, Krzysztof/0000-0002-8040-0412en_US
dc.descriptionWOS: 000348601300004en_US
dc.descriptionPubMed: 24343051en_US
dc.description.abstractBackground: In Europe, health-care policies are determined at a national level and differ between countries. This analysis from a prospective, longitudinal, non-interventional study aimed to describe patterns in the clinical monitoring and treatment of chronic hepatitis B (CHB) in five European countries. Methods: Country-specific cohorts of adult patients with compensated CHB managed in clinics in Germany, France, Poland, Romania and Turkey were followed for up to 2 years between March 2008 and December 2010. Results: A total of 1,267 patients were included. Baseline age and gender distribution were similar across countries for patients who were treated (n=567) and untreated (n=700) at baseline. Most treated patients were receiving monotherapy at baseline, most frequently with entecavir or tenofovir in Germany, France and Turkey, and with lamivudine in Poland and Romania. Use of pegylated interferon was more frequent in Poland and Romania than in other countries. In Romania monotherapy with entecavir increased after it became reimbursed in 2008. Hospitalizations during follow-up were more frequent in Romania (1.45 hospital days/patient-year) and Poland (1.81 days/patient-year) than in Turkey, France and Germany (0.00, 0.05 and 0.10 days/patient-year, respectively); clinic visits were more frequent in Poland (3.20 versus 0.30-1.78 visits/patient-year across other countries). Conclusions: These results illustrate country-specific patterns in the management of CHB patients across Europe. Observed monitoring patterns, hospitalization rates and other health-care utilization may be related to cost and reimbursement issues; however, further study in individual countries would be required to confirm these (post hoc) observations.en_US
dc.language.isoengen_US
dc.publisherInt Medical Press Ltden_US
dc.relation.isversionof10.3851/IMP2719en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleChronic hepatitis B monitoring and treatment patterns in five European countries with different access and reimbursement policiesen_US
dc.typearticleen_US
dc.contributor.departmentOMÜen_US
dc.identifier.volume19en_US
dc.identifier.issue3en_US
dc.identifier.startpage245en_US
dc.identifier.endpage257en_US
dc.relation.journalAntiviral Therapyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record